This technology is a method that integrates multi-omics data to accurately classify glioblastoma (GBM) tumor subtypes and identify functional pathways.
Specific tumor subtypes have different disease progression and responsivity to treatment. Although transcriptomics is used to classify certain tumor subtypes in cancers such as breast cancer, classification methods have failed in accurately identify the subtypes of GBM and their respective prognoses and treatment options.
This technology integrates multi-omics (single cell RNA sequencing and bulk sequencing) to classify different subtypes of GBM tumors. Four functional states are identified: proliferative, mitochondrial, glycolytic/plurimetabolic, and neuronal. Subtype analysis reveals that mitochondrial GBM has the most optimal clinical outcome and responds favorably to oxidative phosphorylation inhibitors. This pipeline can be expanded beyond GBM to identify tumor subtypes from different cancers and its ability to characterize subtypes based on functional pathways will aid in identifying therapeutic targets to improve diagnoses and treatment strategies.
This technology has been tested using human high-grade glioma samples.
Anna Lasorella, M.D.
IR CU21156
Licensing Contact: Kristin Neuman